3D Medicines (Sichuan) Co., Ltd.

11 clinical trials · Sponsor

Record	Firm	Date
Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers (NCT04910386)	3D Medicines (Sichuan) Co., Ltd.	2027-06-01
Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC (NCT06123754)	3D Medicines (Sichuan) Co., Ltd.	2023-11-17
Phase I Trial of Envafolimab for Healthy Male Subjects (NCT05849311)	3D Medicines (Sichuan) Co., Ltd.	2023-05-29
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer (NCT05112991)	3D Medicines (Sichuan) Co., Ltd.	2022-03-04
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors (NCT05024214)	3D Medicines (Sichuan) Co., Ltd.	2021-11-15
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors (NCT04891198)	3D Medicines (Sichuan) Co., Ltd.	2021-08-06
KN035 for dMMR/MSI-H Advanced Solid Tumors (NCT03667170)	3D Medicines (Sichuan) Co., Ltd.	2018-08-22
Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC (NCT03478488)	3D Medicines (Sichuan) Co., Ltd.	2018-04-16
A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors (NCT03248843)	3D Medicines (Sichuan) Co., Ltd.	2017-09-15

Every clearance here is in the API, with alerts when new ones post.